The proposed changes reflect suggestions and requests from staff, leadership and stakeholders, including: 1) in Section R386-702-1, the revised purpose statement to update language regarding emerging infections; previous language was outdated; 2) in Section R386-702-2, added a definition for "Good Samaritan"; 3) in Section R386-702-3, updated language for "Acinetobacter species" to ensure consistency with other drug-resistant organism reporting language; 4) added "Acute Flaccid Myelitis (AFM)", this condition is emerging and of interest nationally, and while it is not nationally-notifiable, CSTE approved standardized criteria for reporting and case classification in 2015; 5) removed "Amebiasis", this condition is not nationally notifiable, and its occurrence is rare in Utah. Most investigated cases lack symptoms and do not end up meeting case definition. Removing it will allow public health resources to remain available for more critical investigations; 6) added "Clostridium difficile" through electronic laboratory reporting (ELR). This will allow for establishment of baseline incidence in Utah, which will allow for better characterization of, and response to, morbidity and mortality associated with this infection; 7) added "Cytomegalovirus (CMV), congenital" via ELR. This is already reportable as per Section R398-4-5. Inclusion in Rule R386-702 will reinforce the reporting requirement, and facilitate laboratory reporting that is indicative of this condition; 8) removed "Echinococcosis", this condition is not nationally notifiable, and is very rare. In Utah, almost all cases are imported. Removing it will allow public health resources to remain available for more critical investigations; 9) updated language for drug-resistant "Escherichia coli" to be consistent with language approved in a CSTE position statement; 10) updated language for drug-resistant "Enterobacter species" to be consistent with language approved in a CSTE position statement; 11) added "(Sin Nombre virus)" to "Hantavirus pulmonary syndrome" in order to clarify that they are associated; 12) simplified language for "Hepatitis C" by removing "acute and chronic infection". This is consistent with language approved in a CSTE position statement; 13) updated language for drug-resistant "Klebsiella species" to be consistent with language approved in a CSTE position statement; 14) clarified language for "Staphylococcus aureus" to indicate reports of this organism, with drug-resistance to vancomycin, from any clinical specimen, are reportable; 15) separated "Streptococcal disease" into two reporting categories: a) streptococcal disease, invasive, due to Streptococcus pneumoniae and Groups A and B isolated from a normally sterile site, and b) streptococcal disease, invasive, other, reported via ELR only. Applicable only to laboratories and hospitals currently participating in ELR; 16) added "meningitis" and "encephalitis" to the list of examples of conditions of interest for "(cccc) Any outbreak, epidemic, or unusual or increased occurrence of illness... "; 17) in Section R386-702-4, made changes in format and minor edits throughout to improve readability; 18) updated language to clarify requirements for ELR; 19) modified the list of conditions for which negative laboratory result reporting is required as follows: a) added "Cytomegalovirus (CMV)", b) removed "Salmonellosis", c) removed "STEC", d) added "Lyme disease", and e) added "Syphilis"; 20) added "Creutzfelt-Jakob Disease and other suspected prion diseases" to the list of "Immediately Reportable Conditions"; 21) modified language under "Confidentiality of Reports" to clarify allowance of information sharing with attending clinicians and public health workers, and to address sharing of information related to good Samaritans who may aid a person with an infectious disease; 22) in Section R386-702-6, added language regarding fees for testing based on new criteria and procedures for charging for rabies-related testing; and 23) in Section R386-702-13, updated links and references as needed.